How formal recommendations, consensus statements, and expert reviews shape practice
Why this spoke matters
Cold agglutinin disease is rare, mechanistically distinctive, and therapeutically evolving. That combination makes guidance especially valuable, but also especially easy to misuse.
Formal guidelines, consensus statements, and expert reviews help clinicians avoid common errors: diagnosing CAD from a cold agglutinin titer alone, treating it like warm autoimmune hemolytic anemia, relying on corticosteroids, missing secondary cold agglutinin syndrome, or overlooking transfusion and perioperative precautions.1
But guidance does not remove the need for judgment. Some recommendations were written before complement-directed therapy entered routine practice. Some address autoimmune hemolytic anemia broadly rather than CAD specifically. Others provide expert consensus rather than high-grade trial evidence.
Much of CAD practice rests on expert consensus, observational data, nonrandomized trials, and evolving drug-specific evidence rather than large head-to-head comparative trials.
The central principle is this:
Guidelines define reasonable pathways. They do not determine which pathway best fits the patient in front of you.
What kinds of guidance exist?
CAD practice is shaped by several types of sources. They are related, but not equivalent.
| Source type | What it contributes | How to use it | Main caution |
|---|---|---|---|
| Formal guidelines | diagnostic structure, transfusion principles, supportive care, broad treatment recommendations | use as a safety framework and standard-of-care anchor | some recommendations predate newer CAD-specific therapies |
| Consensus statements | standardized definitions and expert-agreed diagnostic/treatment principles | use to harmonize terminology and avoid idiosyncratic practice | not always evidence-graded like formal guidelines |
| “How I treat” articles | practical expert sequencing and real-world judgment | use for bedside decision-making and nuance | reflects expert interpretation and experience |
| Contemporary reviews | updated treatment landscape, mechanisms, phenotypes, emerging therapies | use to understand what has changed since older guidelines | not formal recommendations |
| Drug-specific reviews | mechanism, trial data, safety, regulatory positioning | use for focused therapy understanding | may emphasize one treatment axis |
This spoke focuses on clinical practice guidance, broadly defined: formal guidelines, consensus recommendations, and expert reviews that shape how CAD is diagnosed and managed.
Guidance in CAD must also be read historically. The 2017 BSH guidelines remain highly useful for diagnosis, transfusion safety, supportive care, and secondary AIHA framing, but they predate approved complement-directed therapy. The 2020 international consensus standardized definitions and treatment principles but still reflected a period before sutimlimab entered routine practice. Contemporary reviews add the modern layer: complement inhibition is now part of the therapeutic landscape, but its role must still be interpreted alongside clone-directed therapy, supportive care, access, safety, and patient priorities.2
The core areas of agreement
Across guidelines, consensus statements, and expert reviews, several themes recur.
| Domain | Guidance themes | Why it matters |
|---|---|---|
| Diagnosis | establish hemolysis, perform monospecific DAT, interpret cold agglutinin testing in light of thermal amplitude, evaluate for clonal or secondary drivers | CAD is a pattern diagnosis, not a single-test diagnosis |
| Classification | distinguish primary CAD from secondary cold agglutinin syndrome | prognosis, treatment logic, and follow-up differ |
| Supportive care | use cold avoidance, warming, transfusion precautions, infection management, and perioperative planning | supportive care is active risk control |
| Treatment indication | treat clinically meaningful anemia, transfusion need, disabling symptoms, recurrent exacerbations, or substantial quality-of-life burden | hemoglobin alone should not dictate treatment |
| Ineffective defaults | avoid relying on corticosteroids or splenectomy as durable CAD strategies | CAD is not warm AIHA |
| Clone-directed therapy | rituximab-based approaches remain important for suppressing pathogenic IgM production | targets disease source but response is slower |
| Complement-directed therapy | proximal classical pathway inhibition can rapidly control complement-mediated hemolysis | targets disease expression, not the clone |
| Thrombosis | maintain vigilance and consider prophylaxis in high-risk settings | hemolysis and complement activation create vascular risk |
| Monitoring | follow trajectory, not isolated values | CAD is chronic, fluctuating, and context dependent |
Diagnostic guidance: convergence, not one test
Guidelines and consensus recommendations emphasize that CAD diagnosis requires multiple aligned signals:3
- evidence of hemolysis
- DAT pattern consistent with complement coating, typically C3d-positive with absent or weak IgG
- cold agglutinin testing, including titer and thermal amplitude
- evaluation for a clonal B-cell process
- exclusion of secondary cold agglutinin syndrome when appropriate
This is one of the most important practical points. A cold agglutinin alone does not establish CAD. A positive DAT alone does not establish CAD. Even the classic C3d-positive DAT pattern must be interpreted in the setting of hemolysis, cold antibody behavior, and clinical context.
Even diagnostic thresholds require interpretation. Some guidance has used higher cold agglutinin titer thresholds, whereas contemporary consensus definitions commonly use a titer of at least 1:64 at 4°C while acknowledging occasional clinically relevant cases below that threshold. This reinforces the larger diagnostic principle: titer supports the diagnosis, but it does not replace hemolysis, DAT pattern, thermal behavior, and clinical context.4
The diagnostic question is not “Is there a cold agglutinin?” but “Is there clinically relevant cold antibody–mediated hemolysis, and what is driving it?”
Distinguishing primary CAD from secondary cold agglutinin syndrome
Guidelines also emphasize that primary CAD must be distinguished from secondary cold agglutinin syndrome.
Primary CAD is a chronic clonal disorder, usually driven by a marrow-based IgM-producing B-cell process. Secondary cold agglutinin syndrome occurs in association with another condition, such as infection, autoimmune disease, or overt lymphoma.5
This distinction matters because “secondary” does not simply mean “polyclonal.” Infection-associated cold agglutinins are often transient and reactive. Mycoplasma pneumoniae is classically associated with anti-I cold agglutinins, whereas Epstein–Barr virus has been associated with anti-i patterns. Lymphoma-associated cold agglutinin syndrome may be clonal, but classification is driven by the presence of an overt associated disorder.
| Feature | Primary CAD | Secondary cold agglutinin syndrome |
|---|---|---|
| Clinical context | no overt associated disease driving the syndrome | associated with infection, autoimmune disease, overt lymphoma, or another condition |
| Antibody source | usually persistent monoclonal IgM from marrow-based clone | variable: reactive, polyclonal, oligoclonal, or clonal depending on context |
| Course | chronic or relapsing | often depends on underlying trigger |
| Treatment logic | supportive care, clone-directed therapy, complement-directed therapy, or sequencing | treat underlying condition when relevant; manage hemolysis according to severity |
| Key pitfall | assuming absence of overt lymphoma excludes CAD | assuming all secondary CAS is transient or polyclonal |
Supportive care remains foundational
Guidelines consistently emphasize supportive and preventive care. This includes cold avoidance, protection of extremities, careful transfusion practice, warming measures, treatment of infections, and perioperative thermal protection.6
Supportive care should not be framed as “doing nothing.” It modifies risk and disease expression, even when it does not alter the clonal source.
| Supportive domain | Guidance theme | Practical interpretation |
|---|---|---|
| Cold avoidance | reduce cold exposure, especially acral cooling | useful but not always sufficient |
| Transfusion | transfuse when clinically indicated using warmed precautions | transfusion is safe when handled properly |
| Infection | treat promptly because infections can exacerbate hemolysis | acute-phase complement availability may worsen hemolysis |
| Procedures | maintain normothermia and avoid cold infusions | perioperative planning prevents avoidable exacerbation |
| Observation | monitor patients not requiring immediate therapy | observation is active follow-up, not neglect |
When treatment is indicated
Guidelines and expert reviews generally agree that not every patient with CAD requires pharmacologic treatment. Observation and supportive care may be appropriate for mild, stable disease.
Treatment becomes appropriate when disease produces clinically meaningful burden, such as:7
- symptomatic anemia
- transfusion requirement
- disabling fatigue
- clinically significant hemolysis
- recurrent exacerbations
- severe or function-limiting cold-induced circulatory symptoms
- substantial impairment in quality of life
The key shift is from laboratory threshold to clinical impact.
Treatment decisions should be guided by disease impact, trajectory, mechanism, and patient priorities, not by hemoglobin alone.
What guidance says about ineffective defaults
Older AIHA frameworks were often shaped by warm AIHA, where corticosteroids and splenectomy may have a major role. CAD is different.
Guidelines, consensus statements, and expert reviews caution against relying on corticosteroids as durable CAD therapy. Older guidance allowed limited rescue use in selected acute settings, but contemporary CAD-specific reviews emphasize that corticosteroids are generally ineffective or poorly durable and should not be used as a default long-term strategy. Splenectomy is also biologically mismatched because most chronic CAD hemolysis reflects C3-mediated hepatic clearance rather than splenic Fc-mediated clearance.8
| Therapy | Why it may seem tempting | Why guidance cautions against it in CAD |
|---|---|---|
| Corticosteroids | familiar first-line treatment in warm AIHA | low or inconsistent response; often requires unacceptable doses; not a durable default strategy |
| Splenectomy | useful in some warm AIHA | wrong dominant clearance compartment for typical CAD hemolysis |
| Nonspecific immunosuppression | broad immune suppression may seem plausible | CAD is driven by a specific IgM-producing clone and complement pathway |
| Treating titer alone | high cold agglutinin titers look alarming | titer does not reliably predict pathogenicity; thermal amplitude and clinical context matter |
Clone-directed therapy: targeting the source
Guidelines and expert reviews have long emphasized rituximab-based therapy as a major treatment axis in CAD. Rituximab monotherapy may be used in patients who are frail or unable to tolerate combination therapy. Rituximab-bendamustine is an important option for selected fit patients when deeper clone-directed therapy is appropriate. Rituximab-fludarabine has demonstrated efficacy but is generally used more selectively because of immunosuppression and infection risk.9
Clone-directed therapy is aimed at suppressing the IgM-producing clone sufficiently to reduce pathogenic antibody production over time.
| Approach | Main purpose | Strength | Limitation |
|---|---|---|---|
| Rituximab monotherapy | B-cell depletion | less intensive, useful in frail patients | lower response rate, shorter durability |
| Rituximab-bendamustine | deeper clone-directed suppression | higher response rates, durable remissions in many patients | cytotoxic therapy, delayed response, immunosuppression |
| Rituximab-fludarabine | purine analog–based chemoimmunotherapy | effective in selected patients | greater immunosuppression; used more selectively |
| Emerging B-cell/plasma-cell therapies | target other antibody-producing compartments | promising for refractory disease | investigational or limited evidence |
The major limitation is tempo. Clone-directed therapy can provide durable disease control, but responses may take weeks to months. It is not the fastest way to control severe active hemolysis.
Complement-directed therapy: targeting expression
More recent reviews and regulatory documents have changed the practical landscape by incorporating complement inhibition, especially C1s inhibition with sutimlimab.
Complement-directed therapy targets the downstream classical complement pathway responsible for hemolysis. It can rapidly improve hemolysis markers, raise hemoglobin, and improve anemia-related symptoms, but it does not suppress the underlying IgM-producing clone or eliminate cold agglutinins.10
| Question | Clone-directed therapy | Complement-directed therapy |
|---|---|---|
| What is targeted? | IgM-producing B-cell clone | classical complement pathway |
| Main goal | reduce antibody production over time | rapidly control complement-mediated hemolysis |
| Speed | slower | rapid |
| Durability | may provide treatment-free remissions | usually continuous therapy |
| Effect on clone | yes | no |
| Effect on hemolysis | indirect, delayed | direct, rapid |
| Effect on circulatory symptoms | expected if pathogenic IgM falls | less consistent, because agglutination is not primarily complement-mediated |
The practical distinction is:
Complement inhibition controls disease expression. Clone-directed therapy targets disease origin.
Thrombosis and prophylaxis
Guidelines and reviews recognize thrombotic risk in AIHA and CAD, particularly during active hemolysis or high-risk clinical settings. However, the implication is not routine D-dimer screening or automatic anticoagulation for every patient with CAD.
A practical synthesis is:11
- hospitalized patients with acute hemolysis should generally be assessed for thromboprophylaxis
- high-risk settings such as surgery, immobility, infection, severe exacerbation, active malignancy, or prior thrombosis should increase vigilance
- bleeding risk and clinical context must guide decisions
- in practice, D-dimer should be interpreted within standard thrombosis-assessment frameworks rather than used as a stand-alone trigger for prophylaxis
CAD increases thrombotic vigilance; it does not make thromboprophylaxis automatic in every clinical setting.
Where guidance becomes harder to apply
Guidance is most useful when the phenotype is clear: active complement-mediated hemolysis, classic DAT pattern, primary CAD, or obvious secondary CAS.
It is harder to apply when patients sit at boundaries:
| Clinical boundary | Why guidance is less straightforward |
|---|---|
| mild anemia but severe fatigue | hemoglobin does not fully capture burden |
| hemolysis controlled but acrocyanosis persists | complement inhibition may not address agglutination symptoms |
| low clone burden but severe hemolysis | clone size does not predict hemolytic severity |
| secondary CAS with persistent hemolysis | classification may need reassessment |
| weak IgG DAT positivity | may be CAD with weak IgG or mixed AIHA |
| older guideline applied to modern therapy | recommendations may predate sutimlimab |
| patient eligible for multiple therapies | sequencing depends on urgency, durability, access, toxicity, and priorities |
This is where TBP’s approach matters. Guidelines provide the map, but the clinician must still locate the patient on the terrain.
Practical synthesis
Before applying any CAD recommendation, first locate the source: primary CAD, secondary CAS, or AIHA broadly; pre- or post-sutimlimab era; evidence-graded guideline, consensus statement, or expert review. Then locate the patient: dominant hemolysis, dominant circulatory symptoms, both, or uncertain. Only then does the recommendation become clinically usable.
A guideline-informed approach to CAD might look like this:
| Step | Guideline-informed question | Clinical judgment required |
|---|---|---|
| Confirm hemolysis | Is there objective evidence of hemolysis? | mild or compensated disease can still matter |
| Confirm immune/complement pattern | Is DAT C3d-positive with absent or weak IgG? | weak IgG may require careful interpretation |
| Confirm cold antibody behavior | Is the titer and thermal behavior clinically meaningful? | titer alone is insufficient |
| Classify disease | Primary CAD or secondary CAS? | persistence may change the label over time |
| Evaluate clone | Is there monoclonal IgM or marrow clone? | absence on initial testing does not always exclude primary CAD |
| Decide whether to treat | Is burden clinically meaningful? | fatigue, function, and circulatory symptoms matter |
| Choose axis | Complement-directed, clone-directed, supportive, or combination/sequencing? | urgency, durability, toxicity, access, and patient preference matter |
| Monitor longitudinally | Is disease stable, improving, relapsing, or changing phenotype? | trajectory matters more than isolated values |
Clinical synthesis
Clinical practice guidance in CAD is essential because the disease is rare, specialized, and easily mismanaged if treated as generic autoimmune hemolytic anemia.
Guidelines and consensus statements clarify the foundations: diagnose by convergence, distinguish CAD from secondary CAS, use monospecific DAT, evaluate for clonal disease, avoid ineffective default therapies, and treat when disease burden is meaningful.
Expert reviews and newer therapy-focused literature add the modern layer: CAD management now requires understanding two therapeutic axes, clone-directed therapy and complement-directed therapy, each answering a different clinical question.
The practical principle is:
Use guidelines to discipline judgment, not replace it.
Key takeaways
- guidelines are maps: they define safe and reasonable pathways but do not replace patient-specific interpretation.
- guidance has a timestamp: older recommendations remain useful for foundations but may predate complement-directed therapy.
- diagnosis requires convergence: hemolysis, DAT pattern, cold antibody behavior, and clonal/secondary evaluation must be integrated.
- CAD is not warm AIHA: corticosteroids and splenectomy are poor default strategies for durable CAD management.
- treatment depends on burden: anemia, transfusion need, fatigue, circulatory symptoms, exacerbations, and quality of life all matter.
- therapy must match mechanism: complement-directed therapy controls hemolysis rapidly; clone-directed therapy targets antibody production over time.
- judgment remains central: the hardest decisions occur when symptoms, labs, clone burden, and patient priorities do not line up neatly.
Reflect & Apply
A patient with CAD has hemoglobin 10.2 g/dL, persistent fatigue, winter acrocyanosis, and evidence of low-grade hemolysis. The DAT is C3d-positive, IgG weakly positive, and marrow evaluation shows a small IgMκ-producing B-cell clone.
A guideline can tell you that CAD is present and that treatment may be considered when symptoms are meaningful.
It cannot decide:
Is the dominant burden hemolysis, agglutination, or both?
Is the goal rapid control, durable suppression of antibody production, or continued observation?
How should therapy be aligned with this patient’s risk tolerance, functional burden, and priorities?
Evidence and guidance resources
| Resource | Type | Best use |
|---|---|---|
| Hill et al., BSH primary AIHA guideline, 2017 | formal guideline | diagnosis, DAT, transfusion, primary AIHA/CAD framework |
| Hill et al., BSH secondary AIHA guideline, 2017 | formal guideline | secondary AIHA and secondary cold agglutinin syndromes |
| Jäger et al., International Consensus Meeting, 2020 | consensus recommendations | standardized definitions, diagnostic workup, treatment framework |
| Berentsen, How I treat CAD, 2021 | expert practice review | practical sequencing, clone-directed therapy, sutimlimab positioning |
| Barcellini/Fattizzo, 2024 | contemporary expert review/algorithm | modern treatment algorithm and emerging therapies |
| Berentsen et al., hemolytic vs non-hemolytic symptoms, 2024 | phenotype-focused review | treatment individualization by clinical phenotype |
| Broome, sutimlimab review, 2023 | drug-focused review | mechanism, trial evidence, safety, and positioning of C1s inhibition |
| Berentsen, ASH Education, 2025 | updated expert review | current pathogenesis, diagnosis, and management synthesis |